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Abstract: Background: Burkitt
Lymphoma is common childhood
tumour in sub-Saharan Africa but
the lack of centralized database on
childhood cancer in Nigeria has
made it difficult having a nation-
wide picture of its occurrence in
the country.
Objectives: This study was aimed
at pooling published data from
across the country with the hope
of providing an overview of the
profile of the disease in Nigeria.
Methods: literature search was
carried out on Pub Med/
MEDLINE and Cochrane data-
bases for all articles published
between January 1975 and July
2015 using search strings such as
children, cancer, Burkitt’s, epide-
miology, prevalence, treatment
and Nigeria.  Based on specific
criteria, 39 studies were included.
Results: Burkitt Lymphoma was
the most common childhood ma-
lignancy in most parts of the
country accounting for 18.3-
65.0% of malignant tumours but a
few centers observed Retinoblas-
toma as the most common. There
was a decline in the frequency of
Burkitt lymphoma in Ibadan from
1960-2010 and in Lagos. Peak
ages of occurrence ranged from 5-
10 years, more males and children
from low socio-economic classes
were affected. Different centers
reported predominant involvement
of either the jaw or the abdomen
but there were slightly more cen-
ters with predominance of the jaw.
Retrospective studies  yielded an
estimated survival of 15-23%
while the Event Free Survival
probabilities at two years was 43%
and 48% for the Nigerian centers
that participated in an international
study.
Conclusion: Burkitt Lymphoma is
a common tumour in Nigeria. Es-
tablishment of Cancer registries
for better data capture and funding
for better treatment outcomes is
recommended.
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other extranodal sites4.  Epstein Barr virus (EBV) is
found in nearly all cases. Sporadic Burkitt lymphoma
occurs worldwide; with no specific geographic or cli-
matic association. It accounts for 1%–2% of lymphoma
in adults and up to 40% of lymphoma in children in the
United States5. The abdomen, especially the ileocecal
area, is the most common site of involvement; other
sites that may be involved include the ovaries, kidneys,
omentum, and Waldeyer’s ring. Only about 15% of
cases of sporadic Burkitt Lymphoma harbor the EBV
genome6. Immunodeficiency-associated Burkitt lym-
phoma occurs mainly in patients infected with HIV but
has also been reported in organ transplant recipients7.
Nigeria is the most populous country in Africa and the
country’s 2006 Population and Housing Census placed
the country’s population at 140,431,7908. It is divided
into a Federal Capital Territory and thirty-six states and
Introduction
Burkitt lymphoma is an aggressive B cell Non-
Hodgkin’s lymphoma characterized by a high degree of
proliferation of the malignant cells and deregulation of
the c-MYC gene1. It has three variants namely the en-
demic, sporadic and HIV –associated forms2. The high-
est incidence of the endemic form occurs in the lym-
phoma belt lying between latitude 10 degrees north and
south of the equator and characterized by malaria
holoendemicity2. It is therefore common in Tropical
Africa and in Papua New Guinea3.
Endemic Burkitt lymphoma refers to those cases occur-
ring in African children, usually 4–7 years old, involv-
ing the bones of the jaw and other facial bones, as well
as kidneys, gastrointestinal tract, ovaries, breast, and
the states are divided into six geopolitical zones: North-
West, North-East, North-Central, South-East, South-
South, and South-West. The country lies on the west
coast of Africa between latitudes 4º16' and 13º53' north
and longitudes 2º40' and 14º41' east and therefore falls
within the lymphoma belt8. Burkitt lymphoma is there-
fore expected to be common in Nigeria, given its geo-
graphical location.  Studies from several states of the
country report Burkitt Lymphoma to be the most com-
mon type of cancer in children9–11 but a few have re-
ported the contrary12,13.  A centre within the country has
reported a downward trend in the relative frequency of
Burkitt Lymphoma with respect to other tumours but
this has not been appraised in most parts of the country
12. In terms of clinical presentation, whilst some centres
have reported the jaw or face as the predominant site
affected11,14, others have reported the abdomen as the
most common site15,16.
Incidentally, there is no national cancer registry or data-
base to provide a general view of the situation nation-
wide. There is also paucity of population based Cancer
registries and many of publications on childhood cancer
are based on reports from Pathology departments or
clinical reviews. There is therefore lack of national inci-
dence data for the disease which could serve as baseline
data and guide policy formulation towards management
and control. This is important given the association of
the tumour with malaria and therefore the potential to
control its occurrence with malaria control measures2.
The aim of this study was to compile published data on
Burkitt lymphoma across the country in order to summa-
rize them and provide an overview of the national pat-
tern of the disease. The objectives of this study were to
describe the relative frequency, socio-demographic fea-
tures, predominant clinical sites of involvement and
treatment outcomes of Burkitt lymphoma in Nigeria.
The ultimate aim was to provide a summarized report
that could serve as a proxy for generalizable data in the
absence of a centralized database for childhood cancer.
In addition, it was hoped that any regional differences in
pattern would be highlighted by this review.
Methodology
This was a review of published scientific literature on
Burkitt lymphoma in Nigeria between January 1975 and
July 2015.  Literature search was performed on Pub-
Med / MEDLINE and Cochrane databases for all articles
using search strings or key words such as children, can-
cer, Burkitt’s, epidemiology, prevalence, treatment and
Nigeria. The reference list of articles were also checked
for other articles that were not detected by the biblio-
graphic search.  The inclusion criteria for each analysis
depended on the specific objective targeted by that
analysis. In general, only studies based on cases from
cancer registries or histopathology departments or clini-
cal studies confirmed histologically or cytologically
were included. For analysis of relative frequency of
Burkitt lymphoma, emphasis was placed on studies in-
volving all childhood malignancies including leukae-
mias and solid tumours. Studies that were based on solid
tumours alone were analyzed separately and the ranking
of Burkitt lymphoma stated but frequency figures down-
played since they would not be representative of the
entire spectrum of childhood tumours.
A total of 39 articles on Burkitt Lymphoma in Nigeria
were reviewed. Sixteen studies were from the south west
zone constituting the majority, followed by the North
West, south east and north central zones with 8, 7 and 6
studies respectively while the south-south and north east
zones had two and one articles respectively1, one article
was based on 2 centres).  Clinical or clinic-pathologic
studies were used for analysis of socio-demographic
features and predominant sites of tumour involvement
and in this regard, emphasis was placed on studies that
included all tumours confirmed either by cytology of
fine needle aspirate or histology from a surgical biopsy.
Studies based exclusively on surgical biopsy specimen
were analyzed separately and given less emphasis be-
cause the usual method of diagnosing Burkitt lymphoma
in Africa is through cytology of fine needle aspirates of
accessible tumour and so analyzing only studies based
surgical biopsies is likely to exclude a significant pro-
portion of cases and therefore introduce bias to the re-
sults17.
For centres with multiple publications on Burkitt lym-
phoma over time, the most recent was used for preva-
lence figures. However, for analysis of trend, all studies
that met the inclusion criteria over time were used.
Results
Prevalence
Ten centres reported relative frequency of Burkitt lym-
phoma among all cases of childhood malignant diseases
confirmed cytologically or histologically (Table 1).
Burkitt lymphoma was the commonest in eight of the
centres namely Enugu, Zaria, Jos, Ekiti, Calabar, Sa-
gamu, Abia and Gwagwalada with prevalence ranging
from 18.3 to 65.0% of malignant tumours of child hood
in the various centers9–11,18–22. These centres are spread
across the FCT and five geopolitical zones but excluding
the north east geopolitical zone. Retinoblastoma was the
most common tumour in two centres namely, Ibadan
and Kano with Burkitt lymphoma being the second most
common cancer in both cities12,13
.
Studies from seven   centres were restricted to solid tu-
mours; Burkitt lymphoma was the most common solid
tumour in four centres namely Sokoto, Ilorin, Port Har-
court and Ile-Ife as shown in table 223–26. In the fifth
centre, Zaria, Burkitt Lymphoma and Retinoblastoma
were of equal frequency and ranked highest27.  Out of
the remaining two centres, Jos reported Rhabdomyosar-
coma as the predominant solid tumour accounting for 31
percent of the tumours with Burkitt Lymphoma being
the third most common and accounted for 13.8 percent
of the tumours while in Lagos, Retinoblastoma was
reported to be the predominant tumour and accounted
2
for 21% of the tumours whereas Burkitt Lymphoma











Ekanem19 1992 Calabar South south Burkitt Lymphoma 60 18.3 Ward admissions
Ocheni9 2005 Enugu South east Burkitt Lymphoma 79 24.1 Cancer Registry
Agboola18 2009 Sagamu South west Burkitt Lymphoma 77 36.0 Pathology department
Mohammed 10 2009 Zaria North west Burkitt Lymphoma 329 27.0 Cancer registry/ hospital records
Awolola20 2011 Ekiti South west Burkitt Lymphoma 28 28.6 Pathology department
Okpe11 2011 Jos North-central Burkitt Lymphoma 92 48.9 Ward admissions
Ochicha13 2012 Kano North west Retinoblastoma 438 19.9 Pathology and Haematology
Laboratories
Offiong21 2012 Abuja Federal Capital
Territory
Burkitt Lymphoma 46 43.5 Ward admissions
Babatunde12 2015 Ibadan South west Retinoblastoma 625 11.7 Pathology department
Chineke22 2015 Abia South east Burkitt Lymphoma 40 65.0 Clinical/pathology department
Table 1: Frequency of Burkitt Lymphoma among all childhood cancers in different cities of Nigeria
Table 2: Frequency of Burkitt Lymphoma among childhood solid malignant tumours in different cities















Adelusola26 1995 Ile-Ife South-west Hospital-based All solid tumours Burkitt Lym-
phoma





South-south Hospital-based All solid tumours Burkitt Lym-
phoma
173 41.6 Pathology department
Malami23 2005 Sokoto North-west Hospital-based All solid tumours Burkitt Lym-
phoma
158 35.5 Pathology department







189 14.3 each Pathology Department







274 2.0 Pathology department







181 13.8 Cancer registry





261 44.4 Pathology department
All solid tumours = diagnosed from cytology of fine needle aspirate and histology of tissue biopsy
Trend in relative frequency of Burkitt Lymphoma
A review by Ojesina et al30 observed a decline in preva-
lence in Ibadan from 51.5% in the period 1960 to 1972
reported by Williams31, to 37.1 % in the period 1973 to
1990 reported by Akang32 and subsequently 19.4% in
the period 1991-1999 reported by Ojesina et al30. The
11.7% reported by Babatunde et al for the period 1991-
2010 confirms a consistent decline in the relative fre-
quency of Burkitt lymphoma in Ibadan over time12.
Similarly, a decline in the frequency of Burkitt Lym-
phoma among solid tumours has been reported in Lagos;
from 19.6% reported by Tijani et al33 in the period be-
tween 1974 and 1978 in which it ranked first through,
9.5% reported by Akinsulie et al34 in the period 1988-
1998 in which it ranked third to, 2% reported by Akinde
et al29 for the period 2000-2007.
In Enugu, South eastern Nigeria, Ocheni et al35 re-
viewed the relative frequency of Burkitt lymphoma over
four time periods.  The relative frequency of Burkitt
lymphoma was 37% between 1976-80 reported by
Agugua and Okeahialam36, 26.5% between 1978-82
reported by Obioha et al37,  25.3% from 1989-98  re-
ported by Onwasigwe et al38 and 24.1% between 1999-
2004 reported by Ocheni et al35. Considering the period
between 1978 and 2004, there does not seem to have
been an appreciable change in the frequency of Burkitt
Lymphoma in Enugu.
Age distribution
Fifteen studies described peak ages of occurrence of
Burkitt Lymphoma in children while two studies that
included children and adults described median ages. Out
of the fifteen studies on children, fourteen spread across
all geopolitical zones reported peak ages of 5-10 years
(10,11,13–16,19,22,23,25,27,30,39–41) . Only one study
on children, from Sagamu reported a peak age of 1-5
years (18). Out of the two studies that included children
and adults, Kagu et al42 in Ile-Ife reported a median age
of 9 years while Obafunwa and Akinsete reported a me-
dian age of 10 years43.
Sex distribution
Fifteen studies from nine centres across northern and
southern Nigeria described the sex distribution of pa-
tients with Burkitt lymphoma and all reported male pre-
dominance with a male: female ratio ranging from 1.2-
2.7: 1(10,13–16,19,22,23,27,30,39–42,44,45).
Socio economic status
Studies on Burkitt Lymphoma in Nigeria that have de-
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scribed the socio economic status of children have usu-
ally reported that parents of majority of affected children
belong to the low socio economic class (SEC) but re-
porting format has also lacked uniformity for summari-
zation or comparability. In a retrospective study in
Ibadan, south west Nigeria, by Aderele and Antia: out of
133 children studied, occupation of 121 fathers was
available- 42% were subsistence farmers fathers with no
formal education, 20% were traders while 37% were
artisans like carpenters, drivers, tailors or casual labour-
ers, only one father an assistant superintendent of Police
had a relatively high income15. A prospective study by
the same authors, revealed that none of the children be-
longed to the high social class but most of the patients
were from the lowest socio-economic classes including
58% from class V, the lowest social class46. Oguonu et
al16 in Enugu, south eastern Nigeria, reported that 89%
of children with Burkitt lymphoma lived in rural areas
and most patients belonged to the low SEC 75% of them
being from the lowest socio economic class and 54% of
parents illiterate. Another study from south eastern Ni-
geria, by Chinekeet al22 revealed that 61.5% of Burkitt
Lymphoma patients in Abia state were form a low socio
-economic class. Ibrahim et al41 in Sokoto reported that
all parents in their study belonged to the low income
groups, none had formal education and all mothers were
housewives. In summary, most of the parents were of
the low socioeconomic class and this ranged from 61.5
to 100% of patients where figures are stated.
Clinical presentation
Eleven studies from nine centres that described the clini-
cal features of patients with Burkitt Lymphoma were
studied out of which the jaw was the predominant site
affected in five studies while the abdomen was the pre-
dominant site in the remaining six studies.  The six stud-
ies in which the abdomen was the predominant site in-
clude two from Ibadan, and one each from Enugu, Jos,
Zaria and Sokoto in which the abdomen occurring either
alone or in combination with other sites accounting for
between 32 and 77.8 % of tumours(15,16,39,41,43,47).
The five studies in which the jaw was the predominant
site affected include one each from Abia State,
Maiduguri, Ile-Ife, Calabar and Jos;   the jaw accounted
for between 40.7 and 77 % of cases seen occurring ei-
ther alone or in combination with other sites
(11,14,19,22,42). The study from Jos that had the abdo-
men as the predominant site was published in 1992
while that which had the jaw as the predominant site
was published in 2011. Therefore, using the more recent
data from each centre with multiple figures, the jaw was
predominant in five centres and the abdomen in four out
of the nine centres studied.
Treatment
Seven studies that met the inclusion criteria described
treatments given comprising six local studies and one
international multicenter study. The international study
was included because although it involved three African
countries, survival rates for the Nigerian centres where
presented separately. The local studies were all retro-
spective and each used a variety of treatment regimens
but the predominant regimens used in each study are
shown in table 3. The most commonly used regimen
consisted of Cyclophosphamide, Oncovin and Meth-
otrexate (COM). Other drug treatments given included
Cyclophosphamide, Methotrexate and prednisolone16,
monotherapy with any of cytosine arabinoside, meth-
otrexate, nitrogen mustard15,47, cyclophosphamide16 and
surgery15,39. In addition, intra thecal therapy was given
using cytosine arabinoside or methotrexate or both on
different days16,39,42,47. In some instances, treatment
never took place or was abandoned due to financial con-
straints in procurement of chemotherapeutic agents42.
Complete response rate (defined by complete tumour
regression) was less than 50% in all four studies in
which it was stated (table 3). Most patients had either
partial or non-response. Documented death was highest
in the study from Sokoto (85.2%) in which intrathecal
chemotherapy was not given. This was followed by an
earlier study in Ibadan (77%) in which intrathecal ther-
apy was given only occasionally. Assuming that the non
-responders and partial responders eventually died,
analysis of the complete response rate and the docu-
mented deaths in the present study (with the exclusion
of the study from Zaria in which complete response rate
was not stated), would yield an estimated overall sur-
vival rate that is at best 15-23%.  In a recent multicenter
funded study involving Kenya, Tanzania and Nigeria,
the International Network of Cancer Treatment and Re-
search Protocol 03-06 was used.  The event free survival
probabilities at 2 years for the two Nigerian centres that
participated were 43% at the University College Hospi-
tal, Ibadan and 48% at Obafemi Awolowo University
Teaching Hospital Complex (17).
Table 3: Treatment outcome for patients with Burkitt Lymphoma

























Ibadan 1979 94 - CTX Monother-
apy
48.8 - 77.0
Fasola47 Ibadan 2002 56 10 COAP 22.8 57.9 17.5
Taqi39 Zaria 1987 78 - COM Not stated 33.3
Ibrahim 41 Sokoto 1998 27 - COM Not stated 7.4 85.2
Oguonu16 Enugu 2002 44 - COMP 48.0 35.0 59.1 36.0
Kagu42 Ile-Ife 2004 174 39 COM 29.3 77.9 20.7
CTX: cyclophosphamide
COAP: Cyclophophamide, Vincristine, Cytosine arabinoside, Prednisolone
COM: Cyclophophamide, Vincristine, Methotrexate
COMP: Cyclophophamide, Vincristine, Methotrexate, Prednisolone
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Discussion
This review has provided an overview of the pattern of
occurrence of Burkitt Lymphoma across Nigeria. With
the tumour being the most common childhood malignant
tumour in 10 out of 12 centres for whom data for all
cancers is available, it stands out as the most common
childhood cancer nationwide, accounting for between
18.3-65 percent of tumours. Our results also reveal
Burkitt Lymphoma to be the most common malignant
childhood solid tumour in the country. This study has
also shown that Retinoblastoma rather than Burkitt
Lymphoma is the most common childhood cancer in
Ibadan and Kano, situated in the south western and
northwestern geopolitical zones respectively12,13 and the
most common solid tumour in Lagos, also in the south
western zone of the country.  Considering studies that
were based exclusively on solid tumours, Burkitt Lym-
phoma remained the commonest solid tumour in most
centres with the exception of Jos and Lagos. The placing
of Burkitt lymphoma as the third most common tumour
in the review by Tanko et al28 from Jos needs to be in-
terpreted with caution bearing in mind that Burkitt Lym-
phoma is mostly diagnosed through cytology of fine
needle aspirate and so the Jos study which was based on
histology of solid tumours is likely to have an under-
representation of Burkitt Lymphoma17. The predomi-
nance of Retinoblastoma among solid tumours in Lagos
is similar to the finding in Ibadan which is in the same
geopolitical zone. However, the very low frequency of
Burkitt lymphoma (2%) in the most recent study from
Lagos is a striking feature probably due to the fact that
Akinde et al29 used only histologically diagnosed cases
and so excluded cytologically confirmed cases which
might have included cases of Burkitt Lymphoma.
The downward trend in the frequency of Burkitt Lym-
phoma in Ibadan over time from 51.5% reported by Wil-
liams in 1960 to 11.7% reported by Babatunde et al12 in
the year 2010 is quite significant. This is similar to find-
ings in Lagos revealed in the present study. Although
the exact cause is not clear, it has been attributed to im-
provement in living conditions and better malaria con-
trol measures, given the role of malaria in endemic
Burkitt Lymphoma. Knowledge of the factors responsi-
ble for this decline would be useful in proffering solu-
tions towards reducing the incidence of the disease.
Incidentally, a similar trend was not observed in Enugu.
There is a lack of studies on trend of childhood cancer in
other parts of Nigeria. Such studies, along with popula-
tion based incidence studies are necessary nationwide as
epidemiological tools to guide the formulation of policy
and measures aimed at cancer prevention and control.
The male preponderance of the disease nationwide is in
keeping with established findings in Uganda48. This re-
view has shown the peak age of Burkitt Lymphoma in
Nigeria to be between 5 and 10 years which is similar to
the highest age standardized incidence rate observed in 5
-9 years in Kenya49.
Aderele and Antia in Ibadan observed that 99 percent of
children with Burkitt Lymphoma belonged to the low
socio-economic class. They postulated that frequent
infections due to malnutrition to which children form
low socio-economic background are prone, makes their
immunity too weak to combat the Epstein Barr virus
which is associated with Burkitt Lymphoma15.  The pre-
sent review has shown that between 61.5 and 100 per-
cent of children with Burkitt Lymphoma belong to the
low socio-economic class. This suggests a role for low
socio-economic status in the occurrence of the disease
probably due to associated immunosuppression from
malnutrition or poor malaria control from poor living
conditions. However, controlled studies are required to
establish a firm association between Burkitt Lymphoma
and poverty. None-the-less, the difficulties in managing
affected children imposed by poverty such as difficulties
in investigations, use of suboptimal therapy and aban-
donment of treatment highlight the important role of
poverty in contributing to poor outcome in Nigeria42,47.
This calls for government support to treat children with
Burkitt lymphoma free of charge. Improvement in the
standard of living which is likely to reduce the incidence
of the disease is also recommended.
Different epidemiologic forms of Burkitt Lymphoma are
characterized by particular clinical features. Whilst the
endemic form usually presents with tumours of the fa-
cial skeleton as the predominant site, the abdomen is
usually the predominant site in the sporadic form of the
disease(2).  The present study has revealed that the jaw
and abdomen are the major sites affected in Nigeria, in
nearly equal proportions but with a slight predominance
of the jaw. However, the age group affected and the geo-
graphical location support the belief that the form seen
in the country is the endemic form. There is no obvious
geographical bias with the pattern as the northern and
southern regions of the country each has centres with
jaw and abdominal predominant sites. The findings of
this study are in keeping with those from other African
countries in which the major sites affected are the face
and abdomen with slight preponderance of the face as
seen Ghana and Uganda50,51. The peak ages ranging
from 5-10 years observed in most centres in this review
is also in keeping with findings in Kenya and Ugan-
da49,51. The reason why a peak age of 1-5 years was ob-
served in Sagamu is not clear18.
Data on overall survival and event-free survival from
Burkitt Lymphoma in Nigeria are scarce. This study has
however revealed a poor outcome of treatment of the
tumour in the country due to inability to pay for treat-
ment, frequent abandonment of treatment, use of mono-
therapy and loss to follow up. In some instances, 7.4 –
77.9 % of patients abandoned treatment and up to 18.3
% could not receive treatment41, 42. The chemotherapeu-
tic regimen most frequently used was the COM proto-
col. Complete response rate in the retrospective reviews
was between 22.8 to 48.8 percent.  A study on the pat-
terns of treatment failure in Ibadan by Williams et al52
showed that patients with Partial response and Non-
Response were all dead by the 10th observation month.
Consequently, the partial and non-responders in this
may be assumed to have died. Analysis of the complete
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response rate and the documented deaths in the present
study (with the exclusion of the study from Zaria in
which complete response rate was not stated), would
yield an estimated overall survival that is at best 15-23%
in the retrospective studies.   In the INCTR multicenter
study, the EFS probabilities for the Nigerian sites of 43
and 48 percent are better and reflect the improvement
that may result from support in funding treatment17.  Our
findings are also a sharp contrast to a 5 year survival of
64.7% observed in a South African setting with better
laboratory and treatment facilities53.
Conclusion
Burkitt Lymphoma is the most common childhood ma-
lignancy in Nigeria but some parts of the country have a
declining trend in its frequency. This may be due to im-
proving socioeconomic status and malaria control. Some
areas regions experiencing this decline are observing
Retinoblastoma as the predominant childhood cancer.
The demographic features are in keeping with those in
other parts of the World where endemic Burkitt Lym-
phoma occurs. Affected families are poor and treatment
outcomes bedeviled by financial difficulty in paying for
treatment and abandonment of treatment. There is dearth
of national data on incidence which calls for establish-
ment of cancer registries to provide the true incidence of
the tumour. There is also a need for financial support for
treatment of and long term follow up of affected chil-
dren to facilitate improved outcomes and provide data
on survival.
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